Monday, October 25, 2010

Hubei Biocause Pharmaceutical to invest in propylene production

Hubei Biocause Pharmaceutical plans to to invest 301.96 mln yuan in propylene production, which uses the process of catalytic cracking of C4 olefin. About 200.02 mln yuan will be earmarked for construuction costs and 101.

For more details on Hubei Biocause Pharmaceutical to invest in propylene production click here

Related Posts by Categories



Read daily plastics industry news at Plastemart.com

0 comments: